For the Q2 of 2025, Omeros Corporation (NASDAQ: OMER) announced markedly better financial results, showing notable advancements in crucial clinical initiatives and a reduction in losses.
The company reported a net loss of $25.4 million ($0.43 per share) in Q2 2025, a 54.6% decrease from $56.0 million ($0.97 per share) in Q2 2024. Net loss dropped from $93.2 million ($1.60 per share) in the previous year to $58.9 million ($1.01 per share) for the six-month period ending June 30, 2025.
Omeros has $28.7 million in cash and short-term investments as of June 30, 2025. Through a registered direct offering with Polar Asset Management Partners, the business improved its balance sheet. It raised $20.6 million in net proceeds by selling 5,365,853 shares at $4.10 per share.
Regulatory Progress: Narsoplimab Development
For narsoplimab, their primary MASP-2 inhibitor that targets hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), Omeros accomplished several regulatory milestones.
- BLA Resubmission: In March 2025, the FDA received a successful resubmission of the biologics license application.
- Extended PDUFA Date: In response to information requests, the FDA extended the intended action date to December 26, 2025.
- Labeling: FDA-verified labeling is scheduled to start by October 2025 at the latest.
- Supporting Analyses: Every analysis that the FDA requested showed that narsoplimab was beneficial.
Read More: Gilead Sciences Reports Strong Q2 2025 Results, Raises Full-Year Guidance
European Market Entry
The European Medicines Agency (EMA) received Omeros’ Marketing Authorization Application (MAA) in June 2025. The Committee for Medicinal Products for Human Use will begin a formal review once the EMA concludes validation; the committee’s opinion is anticipated in the middle of 2026.
Pipeline Development Programs
PDE7 Inhibitor Program (OMS527)
The OMS527 program at Omeros, which treats cocaine use disorder, is still supported by the National Institute on Drug Abuse (NIDA). Important advancements consist of:
- Grant Funding: $1.5 million has been received so far out of a total award of $6.24 million over three years.
- Preclinical Completion: NIDA-designed preclinical experiments were successfully finished with no safety concerns.
- Clinical Timeline: Aim to begin in-patient research on cocaine users in the first half of 2026.
Read More: Pfizer Reports Strong Q2 2025 Results, Raises Full-Year EPS Guidance
OncotoX-AML
- Clinical Timeline: 18 to 24 months is when the clinic is expected to open.
- Steering Committee: AML treatment leaders from top cancer hospitals formed the Oncology Clinical Steering Committee.
- Efficacy Data: Proven to be more effective than the current standard of care for AML in both in vitro and in vivo models.
- Broad Application: Effective against AML despite genetic alterations in TP53, NPM1, KMT2A, and FLT3.
Revenue Performance
OMIDRIA Royalties
Based on Rayner Surgical’s $28.6 million in U.S. net sales in Q2 2025, OMIDRIA royalties came to $8.6 million, whereas in Q2 2024, they were $10.9 million on $36.4 million in net sales. Through 2031, all U.S. royalties are paid to DRI directly in accordance with agreements with DRI Health Acquisition LP.
Read More: Eli Lilly Reports Strong Q2 2025 Financial Results with 38% Revenue Growth
Operating Expense Management
Based on Rayner Surgical’s $28.6 million in U.S. net sales in Q2 2025, OMIDRIA royalties came to $8.6 million, whereas in Q2 2024, they were $10.9 million on $36.4 million in net sales. Through 2031, all U.S. royalties are paid to DRI directly in accordance with agreements with DRI Health Acquisition LP.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
